Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - A randomized controlled trial
Autore:
Nachman, SA; Stanley, K; Yogev, R; Pelton, S; Wiznia, A; Lee, S; Mofenson, L; Fiscus, S; Rathore, M; Jimenez, E; Borkowsky, W; Pitt, J; Smith, ME; Wells, B; McIntosh, K;
Indirizzi:
SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA SUNY Stony BrookStony Brook NY USA 11794 diat, Stony Brook, NY 11794 USA Albert Einstein Coll Med, Jacobi Med Ctr, New York, NY USA Albert EinsteinColl Med New York NY USA acobi Med Ctr, New York, NY USA NYU Med Ctr, New York, NY 10016 USA NYU Med Ctr New York NY USA 10016NYU Med Ctr, New York, NY 10016 USA Columbia Univ Coll Phys & Surg, Dept Pediat Infect Dis, New York, NY USA Columbia Univ Coll Phys & Surg New York NY USA ect Dis, New York, NY USA Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Cambridge, MA 02138 USAHarvard Univ Cambridge MA USA 02138 tat AIDS Res, Cambridge, MA 02138 USA Boston Med Ctr, Sect Pediat Infect Dis, Boston, MA USA Boston Med Ctr Boston MA USA Ctr, Sect Pediat Infect Dis, Boston, MA USA Childrens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA Childrens Hosp Boston MA USA 02115 , Div Infect Dis, Boston, MA 02115 USA Childrens Mem Hosp, Div Infect Dis, Chicago, IL USA Childrens Mem Hosp Chicago IL USA Hosp, Div Infect Dis, Chicago, IL USA NICHHD, Pediat Adolescent & Maternal AIDS Branch, Bethesda, MD USA NICHHDBethesda MD USA olescent & Maternal AIDS Branch, Bethesda, MD USA NIAID, Div AIDS, NIH, Bethesda, MD USA NIAID Bethesda MD USANIAID, Div AIDS, NIH, Bethesda, MD USA Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA Univ N Carolina Chapel Hill NC USA 27599 munol, Chapel Hill, NC 27599 USA Univ Florida, Hlth Sci Ctr, Dept Pediat, Jacksonville, FL 32209 USA Univ Florida Jacksonville FL USA 32209 Pediat, Jacksonville, FL 32209 USA San Juan City Hosp, Dept Pediat, San Juan, PR USA San Juan City Hosp San Juan PR USA y Hosp, Dept Pediat, San Juan, PR USA Social & Sci Syst, Sect Pediat Infect Dis, Rockville, MD USA Social & Sci Syst Rockville MD USA Pediat Infect Dis, Rockville, MD USA
Titolo Testata:
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
fascicolo: 4, volume: 283, anno: 2000,
pagine: 492 - 498
SICI:
0098-7484(20000126)283:4<492:NAPRIS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS TYPE-1 RNA; IMMUNODEFICIENCY; ZIDOVUDINE; DIDANOSINE; PROGRAM; PLASMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Nachman, SA SUNY Stony Brook, Dept Pediat, HSC T11,080, Stony Brook, NY 11794 USA SUNY Stony Brook HSC T11,080 Stony Brook NY USA 11794 1794 USA
Citazione:
S.A. Nachman et al., "Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - A randomized controlled trial", J AM MED A, 283(4), 2000, pp. 492-498

Abstract

Context Although protease inhibitors are used routinely in adults with human immunodeficiency virus (HIV) infection, the role of these drugs in the treatment of clinically stable HIV-infected children is not clear. Objective To evaluate the safety, tolerance, and virologic response produced by a change in antiretroviral therapy in HIV-infected children who were clinically and immunologically stable while receiving previous therapy. Design The Pediatric AIDS Clinical Trials Group 338, a multicenter, phase 2, randomized, open-label controlled trial conducted from February 6 to April 30, 1997 (patient entry period); patients were followed up for 48 weeks. Setting Pediatric HIV research clinics in the United States and Puerto Rico. Patients Two hundred ninety-seven antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children aged 2 to 17 years. Interventions Children were randomized to receive zidovudine, 160 mg/m(2) 3 times per day, plus lamivudine, 4 mg/kg 2 times per day (n = 100); the same regimen plus ritonavir, 350 mg/m(2) 2 times per day (n = 100); or ritonavir, 350 mg/m(2) 2 times per day, and stavudine, 4 mg/kg 2 times per day (n= 97). Main Outcome Measure Plasma HIV-1 RNA levels at study weeks 12 and 48, compared among the 3 treatment groups. Results At study week 12, 12% of patients in the zidovudine-lamivudine group had undetectable plasma HIV RNA levels (<400 copies/mL) compared with 52% and 54% of patients in the 2- and 3-drug ritonavir-containing groups, respectively (P<.001). Through study week 48, 70% of children continued receiving their ritonavir-containing regimen. At study week 48, 42% of children receiving ritonavir plus 2 nucleosides compared with 27% of those receiving ritonavir and a single nucleoside had undetectable HIV RNA levels (P =.04);however, similar proportions in each group continuing initial therapy had HIV RNA levels of less than 10 000 copies/mL (58% vs 48%, respectively; P=.19). Conclusions In our study, change in antiretroviral therapy to a ritonavir-containing regimen was associated with superior virologic response at studyweek 12 compared with change to a dual nucleoside analog regimen. More children receiving ritonavir in combination with 2 compared with 1 nucleoside analog had undetectable HIV RNA levels at study week 48.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 23:44:30